Seer, Inc. (SEER) stock experienced an increase of 5.77% in the aftermarket despite any official news. However, the last trading session closed at $15.59 with a decrease of 20.42%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Commercial Release of the Proteograph – More About it
On 10th January 2022, SEER announced the release of the Proteograph Product Suite. The Proteograph Product Suite gives you unrivaled, impartial access to the proteome at a scale equivalent to what next-generation sequencing has done for genetics. Moreover, the solution uses patented designed nanoparticles to generate a one-of-a-kind product that allows for unbiased, deep, and quick proteomics at scale. The Proteograph Product Suite has already received a few Broad Release orders from Seer.
So what?
The company is quite enthusiastic about helping the clients to unravel the mysteries of the proteome so that they may truly begin to comprehend biology in a functional and dynamic manner. Moreover, the company has seen this directly with the Collaboration and Limited Release clients who’ve had access to the product over the last year.
Furthermore, the Proteograph Product Suite enables researchers to scan the complete dynamic range of the proteome with the peptide-level resolution, a fully automated approach, and exceptionally high precision, allowing researchers to conduct deep, impartial proteomics investigations at an unparalleled scale and speed. Last but not the least, SEER is ecstatic to be able to provide this transformative technology to a wider audience.
Launch of Centers of Excellence Program – Worth it?
On 10th January 2022, SEER announced the launch of the centers of excellence program. The Proteograph was used by Biodesix, the first company to join the Centers of Excellence initiative, to design and validate a thorough, impartial proteomics methodology. Moreover, the company is honored to be named the Seer Center of Excellence for biopharma services and marketing. With over 15 years of expertise utilizing proteomics in the laboratory, the company brings a lot of knowledge and is very enthusiastic and prepared to provide guaranteed efficiency and accessibility to the Seer platform for biopharma partners.
